{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:59:37Z","timestamp":1790283577681,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euo.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:03:07Z","timestamp":1790280187000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: Results from a UK Tertiary Renal Cancer Network"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6286-2430","authenticated-orcid":false,"given":"Federica","family":"Sordelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda","family":"Kudva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Nally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Barod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Reekhaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzahrani","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Patki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha El","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Sedigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2 Maria","family":"Buffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Boleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.09.002_b0005","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0015","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.09.002_b0020","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.3390\/ijms24044243","article-title":"Adjuvant therapy for renal cell carcinoma: hype or hope?","volume":"24","author":"Cosso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.09.002_b0025","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2025.43.16_suppl.4514","article-title":"Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Haas","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.09.002_b0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.09.002_b0040","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (Prosper ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11934-005-0062-x","article-title":"Surveillance following radical or partial nephrectomy for renal cell carcinoma","volume":"6","author":"Lam","year":"2005","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euo.2026.09.002_b0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clgc.2023.01.005","article-title":"The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): a systematic review and meta-analysis","volume":"21","author":"Monteiro","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.09.002_b0055","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","volume":"42","author":"Albiges","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0060","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.09.002_b0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.002_b0070","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.21.01090","article-title":"External validation of the 2003 Leibovich prognostic score in patients randomly assigned to SORCE, an international Phase III trial of adjuvant sorafenib in renal cell cancer","volume":"40","author":"Oza","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0075","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S1470-2045(25)00644-8","article-title":"ESMO Congress 2025","volume":"26","author":"Collingridge","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0080","doi-asserted-by":"crossref","first-page":"443.e21","DOI":"10.1016\/j.urolonc.2025.01.003","article-title":"Recurrence after surgery for clear cell and papillary renal cell carcinoma: head-to-head comparison of validated risk scores","volume":"43","author":"Longoni","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.09.002_b0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.002_b0090","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00345-022-04153-6","article-title":"How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?","volume":"40","author":"Fallara","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.09.002_b0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000543278","article-title":"Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort","volume":"109","author":"Mattigk","year":"2024","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2026.09.002_b0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00262-025-04230-w","article-title":"Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study","volume":"74","author":"Kopp","year":"2025","journal-title":"Cancer Immunol Immunother"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:03:10Z","timestamp":1790280190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S2588931126002506"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: Results from a UK Tertiary Renal Cancer Network","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier B.V. on behalf of European Association of Urology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}